Actor Portrayal

Embrace fast-acting relief and get back to feeling your best, conquering the cold with confidence.

ColdClear is:

The only non-drowsy formulation

approved by the FDA^1,4

Easy and ready to use

so caregivers don’t have to play the pharmacist¹

Available for as little as $5*

for commercially insured patients, and covered by every state Medicaid⁸

IMPORTANT SAFETY INFORMATION

For ColdClear

Indications:

ColdClear is indicated for the relief of symptoms associated with the common cold, including nasal congestion, runny nose, sneezing, sore throat, and coughing.

Warnings:

Allergy Alert: Do not use ColdClear if you have a known allergy to any of the active ingredients or components of this medication.
Medical Consultation: Consult a healthcare professional before using ColdClear if you have any underlying medical conditions, including but not limited to heart, liver, kidney, or respiratory disorders.
Pregnancy and Nursing: ColdClear should not be used by pregnant or nursing women without medical supervision.
Age Restriction: ColdClear is not recommended for children under 6 years old.

Precautions:

Dosage Instructions: Follow the recommended dosage instructions provided on the product label. Do not exceed the stated dosage, as it may lead to adverse effects.
Other Medications: Inform your healthcare professional about any other medications you are taking, as there could be potential interactions with ColdClear.
Driving and Operating Machinery: ColdClear is formulated to be non-drowsy; however, individual responses may vary. Use caution when driving or operating machinery until you know how this medication affects you.
Duration of Use: If symptoms persist beyond the recommended duration of use or worsen, seek medical attention promptly.
Alcohol Interaction: Avoid consuming alcohol while taking ColdClear, as it may intensify certain side effects.

Side Effects:

Common side effects of ColdClear may include mild dizziness, headache, upset stomach, or mild allergic reactions (e.g., skin rash, itching). Discontinue use and seek medical attention if any severe allergic reactions occur.

Storage:

Store ColdClear at room temperature, away from direct sunlight, heat, and moisture. Keep out of reach of children.

Overdose:

In case of accidental overdose or ingestion of more than the recommended amount of ColdClear, seek immediate medical attention or contact a Poison Control Center.

Important Note:

This ISI summary does not cover all possible precautions, side effects, or drug interactions associated with ColdClear. For a comprehensive understanding of the medication, carefully read the product label and consult with a healthcare professional. If you experience any unexpected or severe reactions while using ColdClear, discontinue use and seek medical assistance promptly.

Manufacturer:

ColdClear Pharmaceuticals, Inc.
Address: [Manufacturer's Address]
Customer Service: [Manufacturer's Customer Service Contact]

Overdose:

In case of accidental overdose or ingestion of more than the recommended amount of ColdClear, seek immediate medical attention or contact a Poison Control Center.

Revision Date: [Insert Revision Date]

(Note: The above ISI information is a fictional example and should not be considered as an actual representation of a real product.)

Important Safety Information

Contraindications

History of serious hypersensitivity reactions to pegylated L-asparaginase
History of serious thrombosis during L-asparaginase therapy
History of serious pancreatitis during previous L-asparaginase treatment
History of serious hemorrhagic events during previous L-asparaginase therapy
Severe hepatic impairment

WARNINGS and PRECAUTIONS

Hypersensitivity: Grade 3 and 4 hypersensitivity reactions including anaphylaxis have been reported in clinical trials with ASPARLAS with an incidence of 7% to 21%. Because of the risk of serious allergic reactions, administer ASPARLAS in a clinical setting with resuscitation equipment and other agents necessary to treat anaphylaxis. Premedicate patients 30-60 minutes prior to administration of ASPARLAS. Observe patients for 1 hour after administration. Discontinue ASPARLAS in patients with serious hypersensitivity reactions.

Pancreatitis: Cases of pancreatitis have been reported in clinical trials with ASPARLAS with an incidence of 12% to 16%. Inform patients of the signs and symptoms of pancreatitis, which, if left untreated, could be fatal. Assess serum amylase and/or lipase levels to identify early signs of pancreatic inﬂammation. Discontinue ASPARLAS in case of suspicion of pancreatitis. If pancreatitis is conﬁrmed, do not resume ASPARLAS.

Please see Full Prescribing Information.

Thrombosis: Serious thrombotic events, including sagittal sinus thrombosis, have been reported in clinical trials with ASPARLAS with an incidence of 9% to 12%. Discontinue ASPARLAS in patients experiencing serious thrombotic events.

Hemorrhage: Hemorrhage associated with increased prothrombin time (PT), increased partial thromboplastin time (PTT), and hypoﬁbrinogenemia have been reported. Evaluate patients with signs and symptoms of hemorrhage with coagulation parameters including PT, PTT, and ﬁbrinogen. Consider appropriate replacement therapy in patients with severe or symptomatic coagulopathy.

Hepatotoxicity: Hepatotoxicity and abnormal liver function, including elevations of transaminase, bilirubin (direct and indirect), reduced serum albumin, and plasma ﬁbrinogen can occur. Evaluate bilirubin and transaminases at least weekly during cycles of treatment that include ASPARLAS through 6 weeks after the last dose of ASPARLAS. In the event of serious liver toxicity, discontinue treatment with ASPARLAS and provide supportive care.

ADVERSE REACTIONS

The most common grade 3 and above adverse reactions (incidence ≥10%) for patients receiving ASPARLAS with multiagent chemotherapy observed in the DFCI clinical trial are elevated transaminases (52%), increased bilirubin (20%), pancreatitis (18%) and abnormal clotting studies (14%). There was 1 fatal adverse reaction (multi-organ failure in the setting of chronic pancreatitis associated with a pancreatic pseudocyst). Not all grade 1 and 2 adverse reactions were collected prospectively.